Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
Pending
verification pending
Revenue YoY
13.4%
reported change
EBITDA
₹173 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Mold-Tek delivered a strong Q4 FY26 with 13.4% revenue growth and EBITDA margin expansion of 310 bps to 40.7%, driven by consolidation of Hyderabad units, higher capacity utilization (now ~65%), and a 219% surge in pharma sales to ₹34.3 Cr. Paint segment grew 14.4% with Asian Paints recovering (+17% in Q4) and ABG up 60%. Lubricants declined due to BPCL loss but stabilized. Management guides for 13-15% value growth in FY27, pharma target of ₹50-55 Cr, and EBITDA margin of 42.5-43%. Capex to moderate to ₹80-85 Cr. Key risk: further escalation of West Asia war disrupting raw material supply or demand.
Colored figures show movement against the previous available record.
Guidance to track
- Management targets 50% growth in pharma sales from ₹34.3 Cr to ₹50-55 Cr in FY27.
- Management expects EBITDA margin to improve from 40.7% to 42.5-43% in FY27, driven by operational efficiencies and consolidation benefits.
- Capital expenditure to be reduced to ₹80-85 Cr in FY27, focused on brownfield expansions and pharma capacity.
- Management expects value growth of 13-15% in FY27, driven by paint recovery, pharma expansion, and food/FMCG growth.
Risks flagged
- The war has caused rapid polymer price increases and supply chain disruptions, which could impact margins if price pass-through lags.
- Loss of BPCL business led to a sharp decline in lubricant sales; management expects no recovery as PSUs prioritize pricing.
- Land for new pharma plant in Satara has been delayed by 7-8 months due to bureaucratic issues, pushing commercial production to early 2028.
- Pharma customers have 90-110 day payment cycles, increasing working capital days and potentially straining cash flows.
Key quotes
- We are aiming at at least 210 crores EBITDA for next financial year up from 173. That's a 20% rise.
- Pharma has grown by 37% over the Q4 of last year and overall growth of the full year is more than 200%.
- We are in fact finding our clients coming back in hordes because they worried about the connectivity material procurement abilities.
Research modules